Early Myelosuppression Secondary to Linezolid Use in the Context of Hematologic Malignancy
By: Yi-Lun Wang, Wan-Ju Lee and Tang-Her Jaing
References
- Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program 2017;2017:187–93.
- Han H, Yan H, King KY. Broad-Spectrum Antibiotics Deplete Bone Marrow Regulatory T Cells. Cells 2021;10.
- Selby PR, Shakib S, Peake SL, et al. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. Clin Pharmacokinet 2021;60:727–39.
- Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009;59 Suppl 1:S59–74.
- Nedved AN, DeFrates SR, Hladnik LM, Stockerl-Goldstein KE. Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy. Pharmacotherapy 2016;36:1087–94.
- Zhou D, Shi T, Zhao S, et al. Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. J Clin Pharm Ther 2020;45:755–8.
Language: English
Submitted on: May 10, 2025
Accepted on: Dec 8, 2025
Published on: Jul 14, 2026
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Yi-Lun Wang, Wan-Ju Lee, Tang-Her Jaing, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.